APL-3007, pegcetacoplan (APL-2)
APL3007-GA-201
Phase 2 small_molecule active
Quick answer
APL-3007, pegcetacoplan (APL-2) for Geographic Atrophy Secondary to Age-related Macular Degeneration is a Phase 2 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apellis Pharmaceuticals
- Indication
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active